Alkermes plc. Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent
Alkermes plc. (ALKS) reported Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent of -203.90% for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential · last filed 2015-02-24
- Alkermes plc. effective income tax rate reconciliation, foreign income tax rate differential, percent for fiscal 2014 was -203.90%.
- Alkermes plc. effective income tax rate reconciliation, foreign income tax rate differential, percent for fiscal 2013 was 43.40%.
- Alkermes plc. effective income tax rate reconciliation, foreign income tax rate differential, percent for fiscal 2012 was -51.70%.
| Period end | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 9 month | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 9 month as first filed | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 12 month | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 12 month as first filed |
|---|---|---|---|---|
| 2014-12-31 | -203.90% 10-K · filed 2015-02-24 | |||
| 2013-12-31 | 209.00% 10-K · filed 2015-02-24 | 127.60% 10-KT · filed 2014-02-27 | ||
| 2013-03-31 | 43.40% 10-K · filed 2015-02-24 | 40.50% 10-K · filed 2013-05-23 | ||
| 2012-03-31 | -51.70% 10-KT · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |